Given the tumor suppressor function of CDKN2C in breast cancer, a loss-of-function of CDKN2C may have driven tumor formation in AYA02; therefore, we selected CDK4/6 inhibitors as a potential drug (palbociclib and LY2835219) [33]. The gene discussed is CDKN2C; the disease is neoplasm.